Ideally, antigen-specific CD8+ and CD4+ T cells respond, respectively, to MHC-I and MHC-II cell surface complexes on cancer cells, activating host immune mechanisms that target the tumor for removal [2]. The gene discussed is CD8A; the disease is cancer.